Home » CLINICAL DATA ACHIEVES VALIDATION OF GENETIC BIOMARKER FOR DETERMINING RISK OF CLOZAPINE INDUCED AGRANULOCYTOSIS
CLINICAL DATA ACHIEVES VALIDATION OF GENETIC BIOMARKER FOR DETERMINING RISK OF CLOZAPINE INDUCED AGRANULOCYTOSIS
Clinical Data, Inc., a worldwide leader in providing comprehensive molecular
and pharmacogenomics services as well as clinical diagnostics to improve patient
care, announced today that its PGxHealth division has completed the validation
of a genetic marker that will help identify patients at risk for Clozapine-Induced
Agranulocytosis (CIA), a potentially deadly blood disorder. This gene is located
in the HLA complex, an area that, as has been previously reported, is associated
with CIA.
Genetic
Engineering News
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May